GI Dynamics' EndoBarrier improves glycemic control, aids weight-loss in mildly obese or overweight patients with Type II diabetes, according to a new study.

MassDevice On Call

MASSDEVICE ON CALL — GI Dynamics (ASX:GID) EndoBarrier gastrointestinal implant proved effective in mildly obese and overweight Type II diabetics, according to a new study.

In a non-randomized, single-arm study of 20 patients with Type II diabetes, the EndoBarrier implant lowered blood glucose levels in more than half and led to a statically significant decrease in total body weight loss of 9.4%, according to a press release.

"Our data point to a substantial improvement in glycemic control and other metabolic parameters even among overweight – but not severely obese – diabetic patients during EndoBarrier Therapy," researcher Dr. Ricardo Cohen said in prepared remarks. "These are promising data and suggest that EndoBarrier may play a valuable role for overweight patients struggling to control their diabetes and lose weight."

 Can docs overcome own biases when evaluating conflicts of interest?
A new study recommends 3rd-party conflict of interest policy-making after finding that physicians are biased when evaluating policies.  
Read more